• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Outset Medical Appoints Renee Gaeta as Chief Financial Officer

    6/3/25 4:30:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $OM alert in real time by email

    SAN JOSE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of Renee Gaeta as Chief Financial Officer (CFO), effective immediately. In addition to leading Finance, Ms. Gaeta will have responsibility for Outset's Information Technology and Human Resources organizations. She succeeds Nabeel Ahmed who is leaving the company to pursue other opportunities.

    "Renee brings deep financial and leadership experience to Outset with a proven track record from her roles at publicly traded medical-device growth companies as both a CFO and board member," said Leslie Trigg, Chair and CEO. "She is the ideal fit for Outset as we drive our next phase of growth and our goal to achieve near-term profitability. I want to thank Nabeel for his contributions to Outset and wish him well in his future endeavors."

    With today's announcement, Outset also reiterated its 2025 financial guidance, including expected revenue of $115 million to $125 million and non-GAAP gross margin in the high-30% range.

    Ms. Gaeta most recently served as CFO of Shockwave Medical until its $13 billion acquisition by Johnson and Johnson in May 2024. She was previously CFO at Eko Health, where she also led both finance and human resources, and Establishment Labs, where she played a key role in the company's initial public offering and growing the global business. She has served as a member of the board of directors and the audit committee of Candel Therapeutics since August 2022 and was previously audit committee chair and a board director of SeaSpine Holdings from 2019 until its acquisition in 2023 by Orthofix Medical. She received her Bachelor of Science, cum laude, in accounting from Loyola Marymount University and is a Certified Public Accountant in California.

    "Outset is transforming dialysis care, and I am honored to join the company as its next CFO," said Ms. Gaeta. "Tablo offers clear and compelling clinical, financial and operational value to acute, post-acute and home dialysis providers. I look forward to playing an important role in helping drive Outset to achieve its growth and profitability goals."

    About Outset Medical, Inc.

    Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the company's possible or assumed future results of operations and financial position, including expectations regarding projected revenues and non-GAAP gross margin. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of the company's filings with the Securities and Exchange Commission, including its most recent annual and quarterly reports. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

    Contact

    Jim Mazzola

    Investor Relations

    [email protected]



    Primary Logo

    Get the next $OM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OM

    DatePrice TargetRatingAnalyst
    8/8/2024$6.00 → $3.00Outperform → Sector Perform
    RBC Capital Mkts
    6/21/2024$5.00 → $6.00Sector Perform → Outperform
    RBC Capital Mkts
    4/8/2024$6.00Buy
    BTIG Research
    4/5/2024$6.00Neutral → Buy
    CL King
    1/12/2024$14.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    10/13/2023$32.00 → $3.00Buy → Underperform
    BofA Securities
    8/17/2023Neutral
    CL King
    11/11/2022$23.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $OM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

      SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

      11/12/24 4:53:46 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

      SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

      11/12/24 4:26:01 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

      SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

      11/12/24 10:32:13 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    SEC Filings

    See more
    • SEC Form S-8 filed by Outset Medical Inc.

      S-8 - Outset Medical, Inc. (0001484612) (Filer)

      6/5/25 4:00:45 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Outset Medical, Inc. (0001484612) (Filer)

      6/3/25 4:35:27 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SD filed by Outset Medical Inc.

      SD - Outset Medical, Inc. (0001484612) (Filer)

      5/29/25 4:05:14 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    Leadership Updates

    Live Leadership Updates

    See more

    $OM
    Financials

    Live finance-specific insights

    See more
    • Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors

      SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O'Boyle's appointment, the company also announced that Dale E. Jones has stepped down from the Board. "Kevin's over 20 years of healthcare leadership experience span roles as CFO of several publicly traded companies and as a board director of 6 public medical device companies," said Leslie Trigg, Chair and CEO. "His expertise in c

      5/14/25 9:00:00 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo Announces Leadership Transition

      Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

      1/21/25 4:00:00 PM ET
      $MASI
      $NARI
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • Outset Medical Names Business Leader Dale E. Jones to Board of Directors

      Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company reducing the cost and complexity of dialysis, today announced the appointment of Dale E. Jones to its Board of Directors. "Dale brings more than 30 years of experience in building diverse and dynamic teams to Outset at a time of exceptional growth for our team," said Chair and CEO Leslie Trigg. "He leads with purpose and deeply understands the role values and culture play in building high-performance organizations, critical traits as we focus on transforming dialysis." Mr. Jones is a Senior Advisor at Diversified Search Group, and previously served as its CEO for more than eight years. He began his career in banking

      4/25/22 4:00:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined

      SAN JOSE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2025. First Quarter and Recent Highlights Net revenue of $29.8 million grew 6% from the prior-year period.Tablo console revenue grew 23% from the fourth quarter.Recurring revenue consisting of Tablo consumables and services grew 20% over the prior-year period to $22.7 million. Outset shipped its 3 millionth Tablo treatment during the quarter, adding 1 million treatments over a period of approximately 12 months.Gross ma

      5/7/25 4:02:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

      SAN JOSE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter 2025 after the close of trading on Wednesday, May 7, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on

      4/16/25 4:32:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN JOSE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter, Year-End Highlights Net revenue of $29.5 million in the fourth quarter and $113.7 million in 2024 were both ahead of the company's prior guidance and preannouncement in January.Gross margin of 36.5% (37.7% on a non-GAAP basis) in the fourth quarter increased 220 basis points sequentially from the third quarter and 11 percentage points from the fourth quarter of 2023. Gross margi

      2/19/25 4:03:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Outset Medical downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Outset Medical from Outperform to Sector Perform and set a new price target of $3.00 from $6.00 previously

      8/8/24 6:47:35 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded Outset Medical from Sector Perform to Outperform and set a new price target of $6.00 from $5.00 previously

      6/21/24 6:53:06 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BTIG Research initiated coverage on Outset Medical with a new price target

      BTIG Research initiated coverage of Outset Medical with a rating of Buy and set a new price target of $6.00

      4/8/24 7:26:20 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $OM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Outset Medical to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

      SAN JOSE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will present at the Goldman Sachs 46th annual Healthcare conference on Wednesday, June 11, 2025, at 11:20 a.m. Eastern time. A live and archived webcast of the presentation will be available on the "Investors" section of the Outset website at https://investors.outsetmedical.com/. About Outset Medical, Inc.Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hem

      6/5/25 9:05:00 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical Appoints Renee Gaeta as Chief Financial Officer

      SAN JOSE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of Renee Gaeta as Chief Financial Officer (CFO), effective immediately. In addition to leading Finance, Ms. Gaeta will have responsibility for Outset's Information Technology and Human Resources organizations. She succeeds Nabeel Ahmed who is leaving the company to pursue other opportunities. "Renee brings deep financial and leadership experience to Outset with a proven track record from her roles at publicly traded medical-device growth companie

      6/3/25 4:30:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors

      SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O'Boyle's appointment, the company also announced that Dale E. Jones has stepped down from the Board. "Kevin's over 20 years of healthcare leadership experience span roles as CFO of several publicly traded companies and as a board director of 6 public medical device companies," said Leslie Trigg, Chair and CEO. "His expertise in c

      5/14/25 9:00:00 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SVP Operations and R&D Nash Marc was granted 29,676 shares, increasing direct ownership by 220% to 43,141 units (SEC Form 4)

      4 - Outset Medical, Inc. (0001484612) (Issuer)

      6/11/25 5:34:53 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • General Counsel Brottem John L. was granted 35,993 shares, increasing direct ownership by 319% to 47,266 units (SEC Form 4)

      4 - Outset Medical, Inc. (0001484612) (Issuer)

      6/11/25 5:33:48 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chair and CEO Trigg Leslie was granted 65,103 shares, increasing direct ownership by 112% to 123,232 units (SEC Form 4)

      4 - Outset Medical, Inc. (0001484612) (Issuer)

      6/11/25 5:32:16 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care